Sexual Side Effects of SSRIs: Why They Happen and What Patients Can Do

Nobody warns you that the medication designed to help you feel better might also make you feel nothing at all, at least in one very specific way.

Sexual side effects are among the most common reasons people quietly stop taking their antidepressants. They affect somewhere between 30% and 80% of people on SSRIs, depending on how the question gets asked, and they drive a meaningful portion of the treatment discontinuation that fuels psychiatry’s adherence crisis. Most patients never mention it. Most prescribers never ask.

That silence costs people their treatment outcomes.

What This Page Covers

• Why SSRIs cause sexual dysfunction
• Which SSRIs are higher-risk
• Five evidence-based strategies for managing the side effects
• What post-SSRI sexual dysfunction means and when to flag it
• How to have the conversation with your prescriber

Why SSRIs Affect Sexual Function

The mechanism is not mysterious. SSRIs work by blocking serotonin reuptake, which increases serotonin availability across mood-regulating circuits. That same serotonin elevation sets off a cascade that disrupts sexual function through at least three distinct pathways.

Dopamine suppression. Elevated serotonin suppresses dopamine activity via the 5-HT2 receptor pathway. Dopamine is the primary driver of sexual desire and the reward experience of sex. When serotonin goes up and dopamine goes down, libido often follows.

Nitric oxide inhibition. SSRIs inhibit the production of nitric oxide, which is the central mediator of genital arousal in both men and women. Nitric oxide drives blood flow to erectile tissue, clitoral engorgement, and vaginal lubrication. When that pathway is suppressed, arousal difficulties, vaginal dryness, and diminished genital sensation follow directly from the pharmacology.

Orgasm delay. Specific serotonin receptor activity, particularly at 5-HT2C and 5-HT3 receptors, directly delays or blocks orgasm. This is actually why SSRIs are prescribed off-label for premature ejaculation. The same mechanism that helps people with premature ejaculation becomes a clinical problem for patients who are simply trying to maintain a satisfying sex life on a maintenance dose.

These three pathways can act independently or in combination, which is why some patients experience primarily libido loss, others experience arousal difficulty, and others experience primarily orgasm delay or anorgasmia.

How Common Is This, Really

The honest answer: more common than clinical trial data suggests, and less commonly reported than it should be.

A 2025 outpatient survey using systematic checklists found that prevalence of antidepressant-associated sexual dysfunction reaches 60 to 80% when patients are asked directly, compared to much lower rates in studies that rely on spontaneous reporting.

A prospective multicenter study of 1,022 outpatients using direct questionnaire assessment found an overall incidence of sexual dysfunction of 59.1% across all antidepressants studied. When patients were assessed by direct interview rather than self-report, rates climbed further.

Surveys found that nearly 50% of women and over 28% of men reported that their prescriber had not explained sexual side effects when starting an SSRI. Meanwhile, 42% of patients reported feeling too embarrassed to raise the issue with their doctor. The result is a problem that affects the majority of patients and is addressed in a minority of cases.

Which SSRIs Carry the Highest Risk

Not all SSRIs affect sexual function equally. The prospective multicenter SALSEX study of 1,022 outpatients provides the most direct per-drug comparison using systematic assessment:

• Citalopram (Celexa): 72.7% incidence
• Paroxetine (Paxil): 70.7% incidence
• Venlafaxine (Effexor, an SNRI): 67.3% incidence
• Sertraline (Zoloft): 62.9% incidence
• Fluvoxamine (Luvox): 62.3% incidence
• Fluoxetine (Prozac): 57.7% incidence
• Mirtazapine (Remeron): 24.4% incidence
• Bupropion (Wellbutrin): rates comparable to placebo

Paroxetine’s higher rate is partly explained by its anticholinergic activity and stronger dopamine suppression. Fluoxetine’s lower rate may relate to its long half-life. The practical implication is that if sexual function is a priority and a medication switch is clinically feasible, the data can inform the choice.

Five Evidence-Based Strategies

1. Watchful Waiting

Some patients experience spontaneous improvement in sexual side effects as the body adjusts to the medication, typically within the first four to eight weeks. This is worth considering if side effects are mild, recent, and not yet significantly affecting quality of life. Research suggests only a minority experience full spontaneous resolution, and waiting indefinitely is not a treatment plan if side effects are affecting medication adherence.

2. Dose Reduction

Sexual side effects are dose-dependent across SSRIs. Reducing to the minimum effective dose that controls depression or anxiety symptoms may reduce the side effect burden meaningfully. This requires prescriber involvement and monitoring to confirm that the lower dose maintains therapeutic effect.

3. Timing the Dose Around Sexual Activity

SSRIs reach peak plasma concentration roughly two to four hours after ingestion. Sexual side effects are most pronounced during that peak window. Some patients find that adjusting the timing of the dose, taking it after planned sexual activity rather than before, reduces the impact. This is a practical, low-risk adjustment worth discussing with a prescriber for those on a once-daily schedule.

4. Adding Bupropion

This is the strategy with the strongest clinical evidence. Bupropion is an NDRI that works by raising dopamine and norepinephrine, directly counteracting the dopamine suppression that SSRIs cause.

A 12-week double-blind, placebo-controlled RCT of 218 women with SSRI-induced sexual dysfunction found that adjunctive bupropion SR 150 mg twice daily improved sexual desire by 86.4% and lubrication by 69.2% compared to placebo. All five domains of sexual function improved significantly in the bupropion group.

A parallel RCT in 234 men found that adjunctive bupropion SR 150 mg twice daily produced a 54.4% increase in total IIEF (erectile function) scores compared to 1.2% in the placebo group, with significant improvements across all five IIEF domains.

A 2025 systematic review and meta-analysis confirmed that bupropion SR 150 mg twice daily is the most effective pharmacological treatment for antidepressant-induced sexual dysfunction in women, with improvements in desire, arousal, and orgasm.

The strongest evidence supports 150 to 300 mg of adjunctive bupropion for reversing SSRI-induced sexual dysfunction in both men and women across the domains of desire, arousal, and orgasm, with benefits occurring regardless of which SSRI is being used or how long the dysfunction has been present.

For men with primarily erectile dysfunction, PDE-5 inhibitors such as sildenafil or tadalafil are well-evidenced as an adjunct, though they address only the arousal and erection component rather than libido or orgasm.

5. Switching to a Lower-Risk Antidepressant

For patients whose depression is well-controlled but whose quality of life is significantly affected by sexual side effects, switching to bupropion monotherapy or mirtazapine is a clinically reasonable option. Both carry sexual side effect rates significantly lower than the SSRI class. The switch requires careful prescriber management, a transition period, and monitoring for mood stability. It is not appropriate for patients with comorbid anxiety as a primary symptom, since bupropion can worsen anxiety in some patients.

Post-SSRI Sexual Dysfunction: What It Means

A separate concern, distinct from treatment-emergent sexual dysfunction, is PSSD: sexual dysfunction that persists after stopping the SSRI entirely.

PSSD is characterized by genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction that continue after drug cessation. The exact prevalence is unknown because it is difficult to study and consistently underreported. Regulatory agencies have taken notice: Australia’s Therapeutic Goods Administration issued a safety update in 2024 advising that all SSRIs and SNRIs would carry warnings about persistent sexual dysfunction after drug cessation. The European Medicines Agency had issued similar guidance earlier.

There is currently no established treatment for PSSD. Patients who experience persistent symptoms after stopping an SSRI should document them and report them to their prescriber.

Why Most Patients Never Bring This Up

The silence around SSRI sexual side effects is not a mystery. It combines embarrassment, the assumption that nothing can be done, and the belief that the medication’s benefits require accepting the side effects as a package deal. None of those assumptions are accurate.

“Sexual side effects are among the most common reasons patients stop an SSRI without telling their prescriber,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “The conversation feels awkward, but it takes about two minutes and there are real options on the other side of it. When I know this is happening, I have a manageable clinical problem. When I do not know, I am watching a patient who appears to be doing well on paper quietly stop their medication for a reason I do not know about.”

What Members Are Saying

SW

S.W., 34

Major Depressive Disorder

“I had been on sertraline for eight months before I mentioned to my prescriber that my libido had completely disappeared. I assumed it was part of being depressed and that I was supposed to live with it. My prescriber added bupropion at a low dose and within six weeks I felt like myself again. I wish I had said something months earlier.”

RT

R.T., 29

Generalized Anxiety Disorder and Depression

“I stopped my escitalopram at month four without telling anyone because of the sexual side effects. Three months later I was back to where I started. When I came back to care, my prescriber explained that we had other options. We switched to a different medication and things are much better. I did not know there was a choice.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Sexual side effects are not a reason to stop an SSRI without talking to your prescriber. They are a reason to have a conversation that most patients avoid and most prescribers do not initiate.

The options are real. Dose adjustment, timing changes, adding bupropion at 150 to 300 mg, and switching medications are all clinically available strategies with evidence behind them. The outcome of that conversation is almost always better than silently stopping and relapsing.

If your medication is affecting your sex life, that is medical information your care team needs. Start your anonymous intake with SiggyMD, where a licensed prescriber reviews every plan and daily check-ins surface the information that changes clinical decisions, including the side effects most people never mention at a quarterly appointment.

Sources

• Montejo AL, et al. Incidence of Sexual Dysfunction Associated With Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients. Journal of Clinical Psychiatry. 2001;62(Suppl 3):10-21.

• Safarinejad MR. Reversal of SSRI-Induced Female Sexual Dysfunction by Adjunctive Bupropion in Menstruating Women: A Double-Blind, Placebo-Controlled and Randomized Study. Journal of Psychopharmacology. 2010;25(3):370-378.

• Safarinejad MR. The Effects of Adjunctive Bupropion on Male Sexual Dysfunction Induced by a Selective Serotonin Reuptake Inhibitor: A Double-Blind Placebo-Controlled and Randomized Study. BJU International. 2010;106(6):840-847.

• Queiroz de Aquino AC, et al. Pharmacological Treatment of Antidepressant-Induced Sexual Dysfunction in Women: A Systematic Review and Meta-Analysis. Clinics (Sao Paulo). 2025.

• Tharmalingam S, Arumugham SS. Treatment-Emergent Sexual Dysfunctions Due to Antidepressants: A Primer on Assessment and Management Strategies. Indian Journal of Psychiatry. 2024;66(3):293-303.

• Healy D, Mangin D. Post-SSRI Sexual Dysfunction: Barriers to Quantifying Incidence and Prevalence. Epidemiology and Psychiatric Sciences. 2024;33:e40.

• Rizvi SJ, Kennedy SH. Psychopharmacology for the Clinician: Managing SSRI-Induced Sexual Dysfunction. Journal of Psychiatry and Neuroscience. 2013;38(5).

• Safak O, et al. Antidepressant-Associated Sexual Dysfunction in Outpatients. BMC Psychiatry. 2025;25:175.

• SingleCare Health. Sex on Antidepressants: Exploring the Sexual Side Effects of SSRIs. Survey of 1,000 patients. Accessed June 2026.